Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium

被引：25

作者：

Sola, Elsa ^{[1
,2
,3
]}

Pose, Elisa ^{[1
,2
,3
]}

Campion, Daniela ^{[4
]}

Piano, Salvatore ^{[5
]}

Roux, Olivier ^{[6
]}

Simon-Talero, Macarena ^{[7
]}

Uschner, Frank ^{[8
]}

de Wit, Koos ^{[9
]}

Zaccherini, Giacomo ^{[10
]}

Alessandria, Carlo ^{[4
]}

Beuers, Ulrich ^{[9
]}

Caraceni, Paolo ^{[10
]}

Francoz, Claire ^{[6
]}

Mookerjee, Rajeshwar P. ^{[11
]}

Trebicka, Jonel ^{[8
]}

Vargas, Victor ^{[7
]}

Serra, Miquel ^{[12
]}

Torres, Ferran ^{[13
]}

Montagnese, Sara ^{[14
]}

Krag, Aleksander ^{[15
,16
,17
]}

Hernaez, Ruben ^{[18
,19
,20
]}

Korenjak, Marko ^{[21
]}

Watson, Hugh ^{[22
,23
]}

Abraldes, Juan G. ^{[24
]}

Kamath, Patrick S. ^{[25
]}

Gines, Pere ^{[1
,2
,3
]}

机构：

[1] Hosp Clin Barcelona, Liver Unit, Villarroel 170, Barcelona 08036, Spain

[2] Univ Barcelona, Sch Med & Hlth Sci, Barcelona, Spain

[3] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

[4] Univ Turin, Citta Salute & Sci Hosp, Div Gastroenterol & Hepatol, Turin, Italy

[5] Univ Padua, Dept Med DIMED, Unit Internal Med & Hepatol UIMH, Padua, Italy

[6] Hosp Beaujon, AP HP, Hepatol & Liver Intens Care Unit, Clichy, France

[7] Univ Autonoma Barcelona, Hosp Vall dHebron & Vall dHebron Res Unit VHIR, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Liver Unit, Barcelona, Spain

[8] Goethe Univ Frankfurt, Dept Internal Med 1, Frankfurt, Germany

[9] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

[10] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[11] UCL, Inst Liver & Digest Hlth, London, England

[12] Univ Pompeu Fabra, Ctr Res Hlth & Econ, Barcelona, Catalonia, Spain

[13] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Biostat & Data Management Core Facil, Barcelona, Spain

[14] Univ Padua, Dept Med, Padua, Italy

[15] Odense Univ Hosp, Dept Gastroenterol & Hepatol, Odense, Denmark

[16] Odense Univ Hosp, Odense Patient Data Exploratory Network OPEN, Odense, Denmark

[17] Univ Southern Denmark, Inst Clin Res, Odense, Denmark

[18] Houston TX Ctr, Michael E DeBakey Vet Affairs Med Ctr, Sect Gastroenterol, Houston, TX USA

[19] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX USA

[20] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA

[21] European Liver Patients Assoc ELPA, Brussels, Belgium

[22] Evotec ID, Lyon, France

[23] Aarhus Univ, Dept Hepatol & Gastroenterol, Aarhus, Denmark

[24] Univ Alberta, Div Gastroenterol, CEGIIR, Cirrhosis Care Clin,Liver Unit, Edmonton, AB, Canada

[25] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA

来源：

JOURNAL OF HEPATOLOGY | 2021年 / 74卷 / 01期

关键词：

Cirrhosis; Liver transplant; Clinical trials; Endpoints; Ascites; AKI; Hepatic encephalopathy; Hyponatremia; Infections; ACLF; Quality of life; QUALITY-OF-LIFE; SPONTANEOUS BACTERIAL PERITONITIS; V-2 RECEPTOR ANTAGONIST; LONG-TERM PROGNOSIS; INTRAHEPATIC PORTOSYSTEMIC SHUNTS; GELATINASE-ASSOCIATED LIPOCALIN; SERUM SODIUM CONCENTRATION; PARACENTESIS PLUS ALBUMIN; URINARY ETHYL GLUCURONIDE; ACUTE KIDNEY INJURY;

D O I：

10.1016/j.jhep.2020.08.009

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V.

引用

页码：200 / 219

页数：20

共 50 条

[31] Adrenal insufficiency is associated with the clinical outcome in patients with decompensated cirrhosis
Cholongitas, Evangelos
Goulis, Ioannis
Kokkonis, George
Chalevas, Parthenis
Gerou, Spyros
Akriviadis, Evangelos
HEPATOLOGY, 2014, 60 : 378A - 378A
[32] Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure
O'Connor, CM
Gattis, WA
Teerlink, JR
Adarns, KF
Gheorghiade, M
AMERICAN HEART JOURNAL, 2003, 145 (02) : S47 - S50
[33] EAHP general assembly updates position paper on clinical trials
Kohl, Stephanie
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (06) : 362 - 363
[34] EEG parameters as endpoints in epilepsy clinical trials-An expert panel opinion paper
Buchhalter, Jeffrey
Neuray, Caroline
Cheng, Jocelyn Y.
D'Cruz, O'Neill
Datta, Alexandre N.
Dlugos, Dennis
French, Jacqueline
Haubenberger, Dietrich
Hulihan, Joseph
Klein, Pavel
Komorowski, Robert W.
Kramer, Lynn
Lothe, Amelie
Nabbout, Rima
Perucca, Emilio
Van der Ark, Peter
EPILEPSY RESEARCH, 2022, 187
[35] Variation in Liver Biochemistries in Patients with Decompensated Cirrhosis: Implications for Assessing Drug-Induced Liver Injury in Clinical Trials
Jurek M.
Mokhtarani M.
Vierling J.M.
Coakley D.F.
Ganju J.
Rowell R.
Scharschmidt B.F.
Pharmaceutical Medicine, 2016, 30 (2) : 95 - 101
[36] Endpoints in clinical trials of fluid resuscitation of patients with traumatic injuries
Wade, CE
Holcomb, JB
TRANSFUSION, 2005, 45 (01) : 4S - 8S
[37] Endpoints in clinical trials involving hemostasis and bleeding in patients with hemophilia
Escobar, MA
TRANSFUSION, 2005, 45 (01) : 2S - 3S
[38] Clinical trials of novel and targeted therapies: Endpoints, trial design, and analysis
Surnan, Vera J.
Dueck, Amylou
Sargent, Daniel J.
CANCER INVESTIGATION, 2008, 26 (05) : 439 - 444
[39] Analysis and Design of Clinical Trials Using Additive Hazards Survival Endpoints
McDaniel, Lee S.
Yu, Menggang
Chappell, Rick
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2019, 11 (03): : 274 - 282
[40] Design and analysis of group sequential clinical trials with multiple primary endpoints
Kosorok, MR
Shi, YJ
DeMets, DL
BIOMETRICS, 2004, 60 (01) : 134 - 145

← 1 2 3 4 5 →